Improving neurocognitive physiopathological aspect of schizophrenia is a current challenge to identify the pathway to develop goal directed clinical interventions in practice.
Aims and objectives: In the present study we will examin the effect of Raloxifine as a selective estrogen modulator and Isradipine as a voltage gated L type calcium channel blocker on improvement of schizophrenic patients cognitive deficits. We designed and performed double blind randomized clinical trials in Zanjan province. 60 patients with schizophrenia or schizoaffective diagnosis, without intellectual disability and systolic blood pressure higher than 100 mmHg and Diastolic pressure above 60 mmHg will recruit in 3 specific groups, will receive 2 times a day, Isradipine capsule 5 mg or Raloxifine tablet 60 mg or placebo in each group. The drugs were given to the patients in capsules with the same color and shape for 6 consequent weeks alongside treatment with conventional antipsychotics. Patients with comorbid chronic diseases in DSM-V axis I, history of life time abuse of substance and any other neurological disorders will be excluded. Initial and final lab data such as (INR, PT, FSH, LH, ALT, AST, ALK, TSH, T3, T4), ECG, positive and negative syndrome scale as well as cognitive tests in specific domains such as attention, processing speed, executive function, verbal memory will be investigated then comparison between groups will be checked.